CD274 and non-small cell lung carcinoma: In a multicenter retrospective study (GOIRC-2018-01) of 1st line pembrolizumab in advanced NSCLC with PS 2 and PD-L1 ≥ 50%, patients with PS 2 due to comorbidities had significantly better outcomes than those with PS 2 due to the disease burden of NSCLC itself (6-month PFS rate 49% vs. 19%, median PFS 5.6 months vs. 1.8 months, OS 11.8 months vs. 2.8 months) [35].